Business Wire

Technology Innovation Institute’s Secure Systems Research Centre Partners with Purdue University on Game-Changing UAV Security Project

10.3.2021 13:29:00 EET | Business Wire | Press release

Share

Technology Innovation Institute (TII), the applied research pillar of the Advanced Technology Research Council (ATRC), today announced that its Secure Systems Research Centre (SSRC) has partnered with Purdue University, a world-renowned US-based public research university. The two entities are collaborating on a three-year sophisticated cybersecurity project to ensure Unmanned Aerial Vehicles (UAVs) can be used safely and efficiently in urban operations.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210310005409/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Dr Shreekant Thakkar, Chief Researcher, Secure Systems Research Centre (SSRC), Technology Innovation Institute (TII) - (Photo: AETOSWire)

Secure Systems Research Centre is one of initial seven dedicated research centres at TII. The research collaboration with Purdue University, titled ‘Cybersecurity for UAS Operations in Urban Environment’, includes the study of security and resilience in cyber-physical and autonomous systems. The project examines safety challenges that Unmanned Aerial Systems (UASs) experience in operating environments. These systems and vehicles are vulnerable to sophisticated cyberattacks in terms of communication, navigation, surveillance, and command and control. The outcome of this research will help other research at Secure Systems Research Centre in the future.

Dr Shreekant (Ticky) Thakkar, Chief Researcher at Secure Systems Research Centre leading the Secure Autonomous Computing work, said: “Our world is becoming increasingly complex. This is evidenced by the rising number of cyberattacks and surveillance breaches that occur daily. We must regain control over critical digital systems. We are optimistic that the research outcomes at TII’s Secure Systems Research Centre will allow us to gain the upper hand in the fight against these malicious attacks.”

He added: “We are delighted to have the Purdue Team led by Prof. Inseok Hwang of School of Aeronautics and Astronautics partner on making cyber-physical and autonomous systems secure and resilient to malware using their state of the art autonomous drone testing facility. This will enable commercial autonomous drones and robots growth in the UAE and worldwide, opening new opportunities to enterprises and making their use safer for all people.”

A multidisciplinary group of researchers from Purdue University will join forces with TII’s Secure Systems Research Centre team.

The research project comprises four phases of development. First, it will carry out a modelling and analysis of UAS security. Second, it will develop algorithms and methodologies for high-assurance autonomy. Third, it will construct an experimental environment and work to simulate safe and secure urban UAS operations. Finally, it will test and validate mitigation strategies in a scaled, mixed-reality testbed.

This three-year project is led by Prof. Inseok Hwang as the principal investigator. Prof. Hwang is assisted on this project by two co-researchers from Purdue University – Prof. James Goppert, a visiting assistant professor at the School of Aeronautics and Astronautics and managing director of the UAS Research and Test Facility; and Prof. Dongyan Xu, the Samuel D. Conte Professor of Computer Science and Director of CERIAS (Center for Education and Research in Information Assurance and Security), Purdue’s cybersecurity research and education center.

Prof. Hwang will assess potential cyberattacks on the systems, Prof. Xu will conduct resource-efficient encryption, multi-UAS communications, and other research from the cyber perspective while Prof. Goppert will test the drones in a special mixed reality environment he will design and build.

Prof. Hwang said: “This landmark project comes at a time of growing reliance on UASs across various sectors – from security to medicine and logistics, and everything in between. We are confident that our partnership will translate into global wins for the international community and lead to many more research milestones in the years to come.”

For more information, please visit www.tii.ae and https://securesystems.tii.ae/

*Source: AETOSWire

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Technology Innovation Institute
Haitham Haddadin
Haitham.Haddadin@tii.ae

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release

Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me

BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release

Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro

Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release

Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab

MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release

The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav

New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release

Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye